PREOPERATIVE PLASMA LEVELS OF INTERLEUKIN-6 AND ITS SOLUBLE RECEPTOR PREDICT DISEASE RECURRENCE AND SURVIVAL OF PATIENTS WITH BLADDER CANCER
The DOI matches its Crossref record.
Abstract
PURPOSE: Elevated levels of interleukin-6 (IL-6) are associated with metastasis and poor prognosis in various malignancies. Since the IL-6 soluble receptor (IL-6sR) potentiates the systemic effects of IL-6, each may independently impact the disease process. We tested the hypothesis that preoperative plasma IL-6 and IL-6sR levels would predict cancer stage and prognosis in patients with transitional cell carcinoma of the bladder. MATERIALS AND METHODS: The study group consisted of 51 patients who underwent radical cystectomy for transitional cell carcinoma and 44 men without cancer. Preoperative plasma levels of IL-6 and IL6sR were measured by enzyme-linked immunosorbent assay and correlated with pathological features and clinical outcome. RESULTS: IL-6 levels were higher in patients with bladder cancer than in healthy controls (p <0.001). In bladder cancer cases elevated levels of IL-6 and IL-6sR were associated with adverse pathological features, including muscle invasion, lymphovascular invasion and lymph node metastases (p <0.05). High levels of IL-6sR were also associated with pathological tumor grade (p = 0.036). In separate multivariate models that included clinical stage and grade IL-6 and IL-6sR levels were independent predictors of lymphovascular invasion, metastases to lymph nodes, disease recurrence and disease specific survival (p <0.05). In a preoperative Cox proportional hazards model IL-6 (p = 0.050) and IL-6sR (p = 0.035) predicted disease specific survival. CONCLUSIONS: We found that plasma IL-6 levels were higher in patients with bladder cancer than in healthy controls. Levels of IL-6 and IL-6sR were associated with cancer stage and metastases, and were strong independent predictors of disease recurrence and disease specific survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Goulet, C. R., Champagne, A., Bernard, G., Vandal, D., Chabaud, S., Pouliot, F., & Bolduc, S. (2019) · BMC Cancer · doi:10.1186/s12885-019-5353-6 · Cited by 322
Kamat, A. M., Hegarty, P. K., Gee, J. R., Clark, P. E., Svatek, R. S., Hegarty, N., Shariat, S. F., Xylinas, E., Schmitz-Dräger, B. J., Lotan, Y., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.09.057 · Cited by 263
Self-citationLippitz, B. E., & Harris, R. A. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1093722 · Cited by 248
Systematic review of the association between circulating interleukin-6 (IL-6) and cancer
Heikkilä, K., Ebrahim, S., & Lawlor, D. A. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.02.047 · Cited by 232
Obesity and risk of bladder cancer: A dose-response meta-analysis of 15 cohort studies
Sun, J.-W., Zhao, L.-G., Yang, Y., Ma, X., Wang, Y.-Y., & Xiang, Y.-B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0119313 · Cited by 133
Metadata
- Authors
- ANDREWS, B., SHARIAT, S. F., KIM, J.-H., WHEELER, T. M., SLAWIN, K. M., & LERNER, S. P.
- Venue
- Journal of Urology
- Published
- 2002-03
- Volume
- 167
- Issue
- 3
- Pages
- 1475-1481
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2141634127
- Cited by
- 102
- References
- 0
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PREOPERATIVE PLASMA LEVELS OF INTERLEUKIN-6 AND ITS SOLUBLE RECEPTOR PREDICT DISEASE RECURRENCE AND SURVIVAL OF PATIENTS WITH BLADDER CANCER. https://app.cochat.ai/papers/10.1016/s0022-5347(05)65348-7
- The paper
- ANDREWS, B., SHARIAT, S. F., KIM, J.-H., WHEELER, T. M., SLAWIN, K. M., & LERNER, S. P. (2002). PREOPERATIVE PLASMA LEVELS OF INTERLEUKIN-6 AND ITS SOLUBLE RECEPTOR PREDICT DISEASE RECURRENCE AND SURVIVAL OF PATIENTS WITH BLADDER CANCER. Journal of Urology. https://doi.org/10.1016/s0022-5347(05)65348-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.